{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:43:36Z","timestamp":1756385016657,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,10,1]]},"abstract":"<jats:p>We present a case of a 73-year-old woman with transfusion-dependent anaemia thought to be secondary to an unidentifiable inflammatory condition. Anaemia evaluation including multiple bone marrow biopsies was unrevealing, with the exception of a non-specific elevation of her erythrocyte sedimentation rate and C-reactive protein. She had no identifiable inflammatory condition and did not meet the criteria for myelodysplastic syndrome. She was empirically treated with lenalidomide and achieved a complete response, suggesting that this immunomodulatory drug could potentially have a role in treating a subgroup of patients with immune-mediated anaemia.<\/jats:p>","DOI":"10.1136\/bcr-2016-217055","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T11:48:22Z","timestamp":1476359302000},"page":"bcr2016217055","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Anaemia with inflammation responding to lenalidomide"],"prefix":"10.1136","volume":"2016","author":[{"given":"Faysal","family":"Haroun","sequence":"first","affiliation":[{"name":"Division of Hematology & Oncology, George Washington University Hospital, Washington DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Mener","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, George Washington University Hospital, Washington DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Elkon","sequence":"additional","affiliation":[{"name":"George Washington University, School of Medicine and Health Sciences, Washington DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Tabbara","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, George Washington University Hospital, Washington DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041809"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.2","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood.V80.7.1639.1639","article-title":"Progress in understanding the pathogenesis of the anemia of chronic disease","volume":"80","author":"Means","year":"1992","journal-title":"Blood"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.3","doi-asserted-by":"publisher","DOI":"10.3390\/nu5083034"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.4","first-page":"1","article-title":"Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS","volume":"36","author":"Valent","year":"2012","journal-title":"Leuk Res"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.5","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-36"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2317"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330126"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.8","unstructured":"Celgene. Analysis of REVLIMID\u00ae (lenalidomide) in patients with non-del-5Q MDS demonstrated improved health related quality of life measures. 2015:1\u20136. http:\/\/ir.celgene.com\/releasedetail.cfm?releaseid=910147"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.9","first-page":"485","article-title":"Low blood counts: immune mediated, idiopathic, or myelodysplasia","volume":"2012","author":"Valent","year":"2012","journal-title":"ASH Educ Progr B"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.10","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2413"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-667063"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq233"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02151.x"},{"key":"2025082805231808000_2016.oct13_1.bcr2016217055.14","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12347"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-217055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:23:22Z","timestamp":1756383802000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-217055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,13]]},"references-count":14,"alternative-id":["10.1136\/bcr-2016-217055"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-217055","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2016,10,13]]}}}